BR0212211A - Diagnóstico de carcinomas - Google Patents
Diagnóstico de carcinomasInfo
- Publication number
- BR0212211A BR0212211A BR0212211A BR0212211A BR0212211A BR 0212211 A BR0212211 A BR 0212211A BR 0212211 A BR0212211 A BR 0212211A BR 0212211 A BR0212211 A BR 0212211A BR 0212211 A BR0212211 A BR 0212211A
- Authority
- BR
- Brazil
- Prior art keywords
- he4a
- soluble
- individual
- detecting
- provides
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
Abstract
"DIAGNóSTICO DE CARCINOMAS". A invenção conduz a composições e métodos para detecção de uma condição maligna, e refere-se a descoberta de formas solúveis e superficiais celulares de polipeptídeos HE4a, incluindo HE4a que é superexpressado em carcinomas ovarianos. Em particular, a invenção providencia uma seq³ência de ácido nucléico codificando HE4a, e também providencia um método de seleção critérios a quanto à presença de uma condição maligna num indivíduo, detectando a reatividade de um anticorpo específico para um polipeptídeo HE4a com uma molécula de ocorrência natural na forma solúvel e/ou de superfície celular numa amostra, de um tal indivíduo, e por seleção criteriosa de hibridização usando uma seq³ência de nucleotídeo de HE4a, bem como outras vantagens relacionadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31653701P | 2001-08-29 | 2001-08-29 | |
PCT/EP2002/009653 WO2003021273A2 (en) | 2001-08-29 | 2002-08-29 | Diagnosis of carcinomas |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0212211A true BR0212211A (pt) | 2004-08-17 |
Family
ID=23229467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0212211A BR0212211A (pt) | 2001-08-29 | 2002-08-29 | Diagnóstico de carcinomas |
Country Status (12)
Country | Link |
---|---|
US (4) | US7270960B2 (pt) |
EP (3) | EP2913673B1 (pt) |
JP (5) | JP2005501549A (pt) |
KR (1) | KR20040062534A (pt) |
CN (1) | CN1813188A (pt) |
BR (1) | BR0212211A (pt) |
CA (1) | CA2459077C (pt) |
ES (1) | ES2628952T3 (pt) |
HK (1) | HK1214346A1 (pt) |
MX (1) | MXPA04001963A (pt) |
RU (1) | RU2004109149A (pt) |
WO (1) | WO2003021273A2 (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030087250A1 (en) * | 2001-03-14 | 2003-05-08 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
US7270960B2 (en) * | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
JP2007504842A (ja) * | 2003-05-29 | 2007-03-08 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | 乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法 |
EP2520654B8 (en) | 2003-08-26 | 2017-04-19 | The Regents of the University of Colorado, a body corporate | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
MXPA06003402A (es) * | 2003-10-07 | 2006-06-27 | Millennium Pharm Inc | Moleculas de acidos nucleicos y proteinas para la identificacion, evaluacion, prevencion y tratamiento de cancer de ovario. |
US20060014221A1 (en) * | 2004-01-21 | 2006-01-19 | Fujirebio Diagnostics, Inc. | Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of mesothelioma |
EP2444805A3 (en) * | 2004-01-21 | 2012-06-20 | Fujirebio America, Inc. | Detection of mesothelin-/megakaryocyte potentiating factor-related peptides in peritoneal fluid for assessment of the peritoneum and the peritoneal cavity |
US20080181892A1 (en) * | 2004-08-11 | 2008-07-31 | Trubion Pharmaceuticals | Binding Domain Fusion Protein |
WO2006119155A2 (en) * | 2005-05-02 | 2006-11-09 | The Brigham And Women's Hospital, Inc. | Diagnostic serum antibody profiling |
ATE438856T1 (de) * | 2005-06-22 | 2009-08-15 | Univ Johns Hopkins | Biomarker für eierstockkrebs: mit ctap3 verwandte proteine |
EP2420576A3 (en) | 2006-01-04 | 2012-03-14 | Fujirebio America, Inc. | Use of HE4 and other biochemical markers for assessment of ovarian cancers |
KR20080094803A (ko) * | 2006-01-27 | 2008-10-24 | 트리패스 이미징, 인코포레이티드 | 난소암의 발병 가능성이 높은 환자를 확인하는 방법 및 그의 조성물 |
US7811778B2 (en) | 2006-09-06 | 2010-10-12 | Vanderbilt University | Methods of screening for gastrointestinal cancer |
MX2009009450A (es) * | 2007-03-09 | 2009-12-01 | Tripath Imaging Inc | Anticuerpos monoclonales para he4 y metodos para su uso. |
JP5144742B2 (ja) * | 2007-03-29 | 2013-02-13 | フジレビオ ダイアグノスティックス インコーポレイテッド | 乳がんの評価のためのhe4の使用 |
US8642347B2 (en) * | 2008-01-31 | 2014-02-04 | The Brigham And Women's Hospital, Inc. | Urinary CA125 peptides as biomarkers of ovarian cancer |
US8476026B2 (en) * | 2008-04-01 | 2013-07-02 | The Brigham And Women's Hospital, Inc. | Biomarkers of ovarian cancer |
US8993347B2 (en) * | 2009-12-17 | 2015-03-31 | Cornell University | Methods for detecting antibodies in mucosal samples and device for sampling mucosal material |
US20130095503A1 (en) * | 2010-01-05 | 2013-04-18 | University Of Cincinnati | Serum spla2-iia as diagnosis marker for prostate and lung cancer |
US20130224772A1 (en) * | 2010-08-26 | 2013-08-29 | University Of Washington Through Its Center For Commercialization | Method for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells |
EP2675911B1 (en) * | 2011-02-17 | 2020-11-04 | Fujirebio Diagnostics, Inc. | Compositions and methods of use for determination of he4a |
WO2012115820A2 (en) * | 2011-02-24 | 2012-08-30 | Vermillion, Inc. | Biomarker panels, diagnostic methods and test kits for ovarian cancer |
CN104039343A (zh) * | 2011-06-06 | 2014-09-10 | 罗得岛州妇婴医院 | 基于he4治疗恶性疾病 |
KR20200044138A (ko) | 2011-06-24 | 2020-04-28 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도 |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
NZ744257A (en) | 2011-06-28 | 2022-10-28 | Inhibrx Inc | Serpin fusion polypeptides and methods of use thereof |
CA2839622A1 (en) | 2011-06-28 | 2013-01-03 | Inhibrx Llc | Wap domain fusion polypeptides and methods of use thereof |
RS56985B1 (sr) | 2011-07-15 | 2018-05-31 | Eisai R&D Man Co Ltd | Antitela protiv alfa receptora folata i njihove upotrebe |
KR20140137347A (ko) | 2012-01-10 | 2014-12-02 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도 |
CN103575902B (zh) * | 2012-08-03 | 2015-07-29 | 河南生生医疗器械有限公司 | 一种时间分辨荧光法四项综合检测卵巢癌试剂盒及其应用 |
WO2016011143A1 (en) * | 2014-07-15 | 2016-01-21 | Temple University Of The Commonwealth System Of Higher Education | Stabilized peptide fragments from redoxin proteins as cancer biomarkers |
CA2996060A1 (en) * | 2015-08-21 | 2017-03-02 | Carsgen Therapeutics, Ltd | Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin |
RU2641094C1 (ru) * | 2016-12-22 | 2018-01-15 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации | Способ ранней диагностики серозной карциномы яичника высокой степени злокачественности на основании изменения клеточного состава эпителия маточной трубы |
WO2020018381A1 (en) * | 2018-07-18 | 2020-01-23 | The Regents Of The University Of California | Kidney injury treatment |
JPWO2020203478A1 (pt) * | 2019-04-02 | 2020-10-08 | ||
US20230243835A1 (en) * | 2020-06-23 | 2023-08-03 | Mitsui Chemicals, Inc. | Adenocarcinoma detection method, and examination kit |
CN117940567A (zh) * | 2021-09-16 | 2024-04-26 | 克迈恩有限公司 | 调控wfdc2的表达的反义化合物 |
WO2023043220A1 (ko) * | 2021-09-16 | 2023-03-23 | 주식회사 큐마인 | Wfdc2의 발현을 조절하는 안티센스 화합물 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4713352A (en) | 1981-08-31 | 1987-12-15 | Sloan-Kettering Institute For Cancer Reseach | Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma |
US4612282A (en) | 1981-12-15 | 1986-09-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Monoclonal antibodies reactive with human breast cancer |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
SE8300693L (sv) | 1983-02-09 | 1984-08-10 | Sven Lofdahl | Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta |
US4579827A (en) | 1983-03-11 | 1986-04-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US5190931A (en) | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
JP2624470B2 (ja) | 1984-10-02 | 1997-06-25 | バイオジェン インコーポレイテッド | ストレプトアビジン様ポリペプチドの製造 |
US5272254A (en) | 1984-10-02 | 1993-12-21 | Biogen Inc. | Production of streptavidin-like polypeptides |
ZA858371B (en) | 1984-11-02 | 1987-03-25 | Oncogen | Monoclonal antibodies for human non-small cell lung carcinomas |
US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
GB8723661D0 (en) | 1987-10-08 | 1987-11-11 | British Bio Technology | Synthetic gene |
US5093245A (en) | 1988-01-26 | 1992-03-03 | Applied Biosystems | Labeling by simultaneous ligation and restriction |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5087617A (en) | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
US5144019A (en) | 1989-06-21 | 1992-09-01 | City Of Hope | Ribozyme cleavage of HIV-I RNA |
US5272262A (en) | 1989-06-21 | 1993-12-21 | City Of Hope | Method for the production of catalytic RNA in bacteria |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
DE4002981C2 (de) | 1990-02-01 | 1998-03-12 | Ihf Inst Fuer Hormon Und Fortp | Humane, Epididymis-spezifische Polypeptide und deren Verwendung zur Therapie und Diagnose männlicher Infertilität |
US5180818A (en) | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
US5135917A (en) | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
US6072039A (en) | 1991-04-19 | 2000-06-06 | Rohm And Haas Company | Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest |
DE4135543A1 (de) | 1991-10-28 | 1993-04-29 | Boehringer Mannheim Gmbh | Rekombinantes core-streptavidin |
ES2252732T3 (es) * | 1992-05-26 | 2006-05-16 | Immunex Corporation | Nueva citoquina que une cd30. |
EP0644938A1 (en) | 1992-05-29 | 1995-03-29 | E.I. Du Pont De Nemours And Company | PRODUCTION OF STREPTAVIDIN FROM $i(BACILLUS SUBTILIS) |
US5935824A (en) * | 1996-01-31 | 1999-08-10 | Technologene, Inc. | Protein expression system |
US6313269B1 (en) | 1997-03-14 | 2001-11-06 | Smithkline Beecham Corporation | Tumor necrosis factor related receptor, TR6 |
WO1999023218A1 (fr) | 1997-11-05 | 1999-05-14 | Sumitomo Electric Industries, Ltd. | PROTEINES DE FIXATION DE p16, GENE DE CES PROTEINES ET ANTICORPS CONTRE CES PROTEINES |
US6783961B1 (en) * | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
GB9810040D0 (en) * | 1998-05-11 | 1998-07-08 | Univ Nottingham | Blood borne tumour markers |
AU769756B2 (en) * | 1998-11-03 | 2004-02-05 | Mitokor | Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CA2296792A1 (en) | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
US6770445B1 (en) * | 1999-02-26 | 2004-08-03 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
DE60028361T2 (de) | 1999-02-26 | 2007-05-10 | Pacific Northwest Research Institute, Seattle | Verfahren und zusammensetzungen zur karzinomdiagnose |
US20030143234A1 (en) | 1999-08-20 | 2003-07-31 | Wenyuan Shi | Anti-microbial targeting chimeric pharmaceutical |
EP1206479A1 (en) * | 1999-08-24 | 2002-05-22 | Texas Biotechnology Corporation | A polynucleotide encoding a human junctional adhesion protein (jam-2) |
WO2001016354A1 (en) | 1999-09-02 | 2001-03-08 | Gene Logic, Inc. | Modulation of he4 in inflammatory and renal diseases |
WO2001018542A2 (en) * | 1999-09-03 | 2001-03-15 | Millennium Pharmaceuticals, Inc. | Identification, assessment, prevention, and therapy of ovarian cancer |
CA2395816A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins and antibodies |
WO2001075177A2 (en) * | 2000-04-03 | 2001-10-11 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tumor markers in ovarian cancer |
WO2002000677A1 (en) | 2000-06-07 | 2002-01-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
WO2002046765A2 (en) * | 2000-11-08 | 2002-06-13 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer |
US20030087250A1 (en) | 2001-03-14 | 2003-05-08 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
IL159015A0 (en) * | 2001-05-25 | 2004-05-12 | Genset Sa | Polypeptides, their preparation and use |
US7270960B2 (en) * | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
AU2003276852A1 (en) | 2002-08-16 | 2004-03-03 | Clinical Microarrays, Inc. | Reading of fluorescent arrays |
US20050181375A1 (en) | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
EP1723428A2 (en) * | 2004-02-19 | 2006-11-22 | Yale University Corporation | Identification of cancer protein biomarkers using proteomic techniques |
DE102004014645A1 (de) * | 2004-03-25 | 2005-10-13 | Mitsubishi Polyester Film Gmbh | Transparente, elektrisch leitfähige, beschichtete Polyesterfolie, Verfahren zu ihrer Herstellung sowie ihre Verwendung |
US20080181892A1 (en) * | 2004-08-11 | 2008-07-31 | Trubion Pharmaceuticals | Binding Domain Fusion Protein |
DE602006002809D1 (de) | 2005-02-16 | 2008-10-30 | Dana Farber Cancer Inst Inc | Verfahren zur erkennung eines ovarialkarzinoms |
WO2006135886A2 (en) | 2005-06-13 | 2006-12-21 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
CA2611173C (en) | 2005-06-24 | 2019-11-12 | Ciphergen Biosystems, Inc. | Biomarkers for ovarian cancer |
EP2420576A3 (en) | 2006-01-04 | 2012-03-14 | Fujirebio America, Inc. | Use of HE4 and other biochemical markers for assessment of ovarian cancers |
CA2703795A1 (en) * | 2006-10-27 | 2008-05-02 | Mount Sinai Hospital | Endometrial phase or endometrial cancer biomarkers |
MX2009009450A (es) * | 2007-03-09 | 2009-12-01 | Tripath Imaging Inc | Anticuerpos monoclonales para he4 y metodos para su uso. |
US20130224772A1 (en) * | 2010-08-26 | 2013-08-29 | University Of Washington Through Its Center For Commercialization | Method for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells |
EP2675911B1 (en) * | 2011-02-17 | 2020-11-04 | Fujirebio Diagnostics, Inc. | Compositions and methods of use for determination of he4a |
-
2002
- 2002-08-28 US US10/233,150 patent/US7270960B2/en not_active Expired - Lifetime
- 2002-08-29 KR KR10-2004-7003017A patent/KR20040062534A/ko not_active Application Discontinuation
- 2002-08-29 EP EP14179937.9A patent/EP2913673B1/en not_active Expired - Lifetime
- 2002-08-29 CN CNA028192680A patent/CN1813188A/zh active Pending
- 2002-08-29 JP JP2003525305A patent/JP2005501549A/ja not_active Withdrawn
- 2002-08-29 MX MXPA04001963A patent/MXPA04001963A/es unknown
- 2002-08-29 BR BR0212211A patent/BR0212211A/pt not_active Application Discontinuation
- 2002-08-29 ES ES14179937.9T patent/ES2628952T3/es not_active Expired - Lifetime
- 2002-08-29 CA CA2459077A patent/CA2459077C/en not_active Expired - Lifetime
- 2002-08-29 WO PCT/EP2002/009653 patent/WO2003021273A2/en active Application Filing
- 2002-08-29 RU RU2004109149/15A patent/RU2004109149A/ru not_active Application Discontinuation
- 2002-08-29 EP EP20020797648 patent/EP1421388A2/en not_active Withdrawn
- 2002-08-29 EP EP20100184645 patent/EP2322933A1/en not_active Withdrawn
-
2007
- 2007-08-08 US US11/890,896 patent/US20090104684A1/en not_active Abandoned
-
2009
- 2009-04-23 JP JP2009104717A patent/JP5188443B2/ja not_active Expired - Lifetime
- 2009-08-06 US US12/536,975 patent/US9090712B2/en not_active Expired - Lifetime
-
2012
- 2012-03-14 JP JP2012056979A patent/JP5797136B2/ja not_active Expired - Lifetime
-
2014
- 2014-01-17 JP JP2014006581A patent/JP2014081386A/ja not_active Withdrawn
-
2015
- 2015-07-27 US US14/809,498 patent/US20160033512A1/en not_active Abandoned
- 2015-10-26 JP JP2015209823A patent/JP2016065870A/ja active Pending
-
2016
- 2016-02-23 HK HK16102022.0A patent/HK1214346A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US20090104684A1 (en) | 2009-04-23 |
JP2009195240A (ja) | 2009-09-03 |
MXPA04001963A (es) | 2005-02-17 |
EP2913673A1 (en) | 2015-09-02 |
JP5797136B2 (ja) | 2015-10-21 |
JP2012161317A (ja) | 2012-08-30 |
EP2322933A1 (en) | 2011-05-18 |
US20030108965A1 (en) | 2003-06-12 |
JP2014081386A (ja) | 2014-05-08 |
HK1214346A1 (zh) | 2016-07-22 |
KR20040062534A (ko) | 2004-07-07 |
US20100047818A1 (en) | 2010-02-25 |
JP5188443B2 (ja) | 2013-04-24 |
EP1421388A2 (en) | 2004-05-26 |
US20160033512A1 (en) | 2016-02-04 |
CA2459077C (en) | 2018-06-05 |
JP2005501549A (ja) | 2005-01-20 |
ES2628952T3 (es) | 2017-08-04 |
US9090712B2 (en) | 2015-07-28 |
US7270960B2 (en) | 2007-09-18 |
WO2003021273A2 (en) | 2003-03-13 |
CA2459077A1 (en) | 2003-03-13 |
CN1813188A (zh) | 2006-08-02 |
WO2003021273A3 (en) | 2003-12-04 |
RU2004109149A (ru) | 2005-05-10 |
EP2913673B1 (en) | 2017-05-31 |
JP2016065870A (ja) | 2016-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0212211A (pt) | Diagnóstico de carcinomas | |
Peng et al. | New prognosis biomarkers identified by dynamic proteomic analysis of colorectal cancer | |
WO2004076679A3 (en) | Serum macrophage migration inhibitory factor (mif) as marker for prostate cancer | |
EP1708745A4 (en) | ANTIBODIES FOR ONCOGEN STRAINS OF HPV AND METHODS OF USE | |
WO2008012362A3 (en) | New protein isoforms and uses thereof | |
WO2009019365A3 (fr) | Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal | |
WO2005103719A3 (en) | Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies | |
ATE474857T1 (de) | Antikörper gegen ein epitop auf agr2, assays und hybridome | |
EP1399739A4 (en) | METHOD AND KITS FOR DIAGNOSIS OF TUMOR ENGENITATION AND DETERMINATION OF RESISTANCE TO THE ANTINEOPLASTIC EFFECTS OF ANTI-STROGEN THERAPY | |
DE502006003717D1 (de) | Bestimmung von kurzkettiger srl-alkoholdehydrogenase (dhrs4) als biomarker für entzündungen und infektionen | |
Malinowsky et al. | UPA and PAI-1 analysis from fixed tissues-new perspectives for a known set of predictive markers | |
BRPI0607016A2 (pt) | marcadores polipeptìdicos para o diagnóstico de cáncer de próstata | |
ATE318935T1 (de) | Bewertungssystem für die vorhersage von krebsrezidiven | |
NO20013563D0 (no) | Fremgangsmåter og prövesett for sekvensering av polypeptider | |
Capello et al. | Phosphorylated alpha-enolase induces autoantibodies in HLA-DR8 pancreatic cancer patients and triggers HLA-DR8 restricted T-cell activation | |
WO2003068268A3 (en) | Treatment, diagnosis and imaging of disease | |
DE60328186D1 (de) | Zusammensetzung für die herstellung von histologischen, autopsischen und zytologischen proben | |
BR0210094A (pt) | Método para medir a proporção de expressão de um gene da classe de genes padrões | |
US8257716B2 (en) | Anti-PDEF antibodies and uses thereof | |
CN105399805B (zh) | 木瓜功能着丝粒抗原多肽及其应用 | |
ATE272718T1 (de) | Verfahren zur bestimmung von disaccharidasen | |
DE60334408D1 (de) | Nsäuren | |
SE0100595D0 (sv) | Immunological detection of prostate diseases and prostatic-related diseases | |
WO2000003687A3 (en) | Potassium channel polypeptide and polynucleotide compositions | |
ES2185419T3 (es) | Oligonucleotido de adn que es especifico de especies meloidogyne, vector de adn y celula huesped que contienen el oligonucleotido, uso y kit. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |